Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies

Barchart · 06/03 11:15


 

Paris, France, June 3, 2024 – 6:00 CEST - ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, provides an update on the clinical development of glenzocimab following the release of results from its phase 2/3 ACTISAVE study.

Read more at globenewswire.com